Repros Therapeutics

11/10/2008 - 05:10 PM

Repros Therapeutics Inc. Files Shelf Registration

11/10/2008 - 06:00 AM

Repros Therapeutics Inc. Reports Third Quarter 2008 Financial Results

10/29/2008 - 04:24 PM

Repros Presentation to Be Webcast from the Oppenheimer 19th Annual Healthcare Conference, the Rodman & Renshaw 10th Annual Healthcare Conference and the 20th Annual Piper Jaffray Healthcare Conference

10/02/2008 - 07:00 PM

Repros Therapeutics Inc. Announces Closing of Previously Announced Direct Registered Offering

09/29/2008 - 08:45 AM

Repros Therapeutics Inc. Announces $15.6 Million Financing

08/21/2008 - 06:00 AM

Repros Therapeutics Inc. Announces No Tumors in First Completed Proellex Animal Carcinogenicity Study

08/18/2008 - 06:00 AM

Repros Therapeutics Inc. Provides Update for US Phase II Endometriosis Study and Completion of QT Interval Dose Selection Screen

08/11/2008 - 06:00 AM

Repros Therapeutics Inc. Reports Second Quarter 2008 Financial Results

07/21/2008 - 06:00 AM

Repros Therapeutics Inc. Announces That the Results of the European Trial Demonstrating Uterine Fibroid Size Reduction in Patients Administered Proellex(R) Will Be in Print in August 2008

07/18/2008 - 12:30 PM

Repros Therapeutics Inc. Announces That Initial Findings for Proellex(R) Show No Tumorigenic Response in a Two-year Carcinogenicity Study in Rats

07/16/2008 - 05:43 PM

Repros Therapeutics Inc. Announces That Proellex(R) Administered to Patients as Cyclic Therapy to Treat the Symptoms of Uterine Fibroids for Up to 30 Months Shows No Adverse Effects on the Endometrium

07/14/2008 - 08:00 AM

Repros to Host Analyst Meeting, July 24, 2008

07/11/2008 - 06:00 AM

Repros Therapeutics Inc. Announces That Proellex Significantly Reduces Pain in a U.S. Phase 2 Clinical Trial in Women with Moderate to Severe Endometriosis

06/30/2008 - 06:00 AM

Repros Therapeutics Inc. Initiates a Comparative Phase 2b Study of Oral Androxal(R) as Compared to Topical Testim(R) Examining Effects on Male Fertility and Testicular Function

06/09/2008 - 06:00 AM

Repros Therapeutics Inc. Announces That Initial Findings for Proellex(R) Show No Gross Cancer Tumors in First Completed Animal Carcinogenicity Study

05/29/2008 - 06:10 PM

Wall Street Media Presents Three Exclusive Video Clips from the 2008 FBR Capital Markets Conference

05/29/2008 - 06:00 AM

Repros Therapeutics Inc. Announces That Initial Findings for Proellex(R) Show No Adverse Effects on the Endometrium after One Year on Drug

05/27/2008 - 05:33 PM

Repros Presentation to Be Webcast from the FBR Capital Markets' 12th Annual Spring Investor Conference

05/12/2008 - 09:59 AM

Repros Therapeutics Inc. Announces That Proellex Shows No Adverse Cardiac Effects In A Pilot Trial

05/09/2008 - 05:23 PM

Repros Therapeutics Inc. Reports First Quarter 2008 Financial Results and Provides Clinical Development Program Overview

05/08/2008 - 02:55 PM

Repros to Report First Quarter 2008 Financial Results on May 9, 2008

03/31/2008 - 11:22 AM

Repros Reports Interim Safety Results From Ongoing One-Year Open Label Study of Proellex(R) in the Treatment of Uterine Fibroids

03/17/2008 - 06:00 AM

Repros Therapeutics Inc. Reports Fourth Quarter and Year End 2007 Financial Results and Provides Clinical Development Program Overview

03/13/2008 - 05:54 PM

Repros to Report Fourth Quarter and Full Year 2007 Financial Results on March 17, 2008

03/07/2008 - 08:00 AM

Repros' Proellex(R) Safety Data Presented At The 13th World Congress of Gynecological Endocrinology

02/22/2008 - 09:15 AM

Repros' IND for the Commencement of Phase III Studies of Proellex(R) in the Treatment of Anemia Associated with Uterine Fibroids is Now Effective

02/08/2008 - 04:20 PM

Repros to Present at the 13th World Congress of Gynecological Endocrinology in Florence, Italy

02/08/2008 - 12:21 PM

Repros Presentation to Be Webcast from The 10th Annual Bio/CEO and Investor Conference 2008

01/31/2008 - 04:18 PM

Repros Announces 2008 Annual Shareholders' Meeting

01/09/2008 - 06:32 PM

Repros and Efficacy Capital Announce Standstill Agreement

01/07/2008 - 05:10 PM

Repros to Present at the 26th Annual JP Morgan Healthcare Conference

12/03/2007 - 06:00 AM

Repros' Lead Product Proellex to Enter Phase 3 for the Treatment of Uterine Fibroid Indications